Servier gets rights to Sorrento's preclinical PD-1 mAb

Sorrento Therapeutics Inc. (NASDAQ:SRNE) granted Servier (Neuilly-sur-Seine, France) an exclusive, worldwide license to STI-A1110, a preclinical mAb against PD-1. Servier expects to study STI-A1110 in combination with its own portfolio candidates.

Sorrento is to receive EUR 25 million ($27.6 million) up front and is eligible for EUR 151 million ($166.5 million) in development and regulatory milestones, EUR 710 million ($782.8 million) in commercial milestones, and royalties. ...